Aqneursa Granule, For Suspension
Product Images NDC 83853-101

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Aqneursa (NDC 83853-101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Intrabio Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Carton Label (Carton Label)

Carton Label (Carton Label)
FDA Label Image

Figure Section 11 (Figure Section 11)

Figure Section 11 (Figure Section 11)
FDA Label Image

Table 4 Section 14 (Table 4 Section 14)

Table 4 Section 14 (Table 4 Section 14)
Table 4 provides a summary of the efficacy results for mSARA and SARA. The Modified Scale for the Assessment and Rating of Ataxia (mSARA) baseline value was 0.98 with a standard deviation of 0.05. The treatment effect of Brand Name versus Placebo was -0.96 with a standard deviation of 0.25. The total change versus baseline for Brand Name was -1.66. The Scale for the Assessment and Rating of Ataxia (SARA) baseline value was 0.95 with a standard deviation of 0.04. The treatment effect of Brand Name versus Placebo was -128 with a standard deviation of 0.31. The total change versus baseline for Brand Name was -1.97. For the placebo group, the total change versus baseline was -0.60. Please note that this description is based on the provided text and may contain errors or inaccuracies.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.